Role of Tyrosine Kinase Inhibitors and Gene Therapy in Retinal Diseases

EP: 1.Impact of First-Line Therapy on Long-Term Outcomes in nAMD and DME

EP: 2.Choosing First-Line Therapy in nAMD or DME

EP: 3.When to Switch to More Efficacious Agents

EP: 4.Real-World Experiences With Faricimab

EP: 5.Real-World Experiences With Aflibercept 8mg

EP: 6.Efficacy and Durability: New Therapies vs Aflibercept 2mg

EP: 7.Perspectives on Retinal Fluid Management

EP: 8.Perspectives on Loading Dose Recommendations for New Therapies

EP: 9.Safety Considerations for New Therapies

EP: 10.The Impact of Biosimilars in Retinal Diseases

EP: 11.The Status of Gene Therapy Development for Retinal Diseases

EP: 12.Considering Safety of Gene Therapy for Retinal Diseases

Now Viewing

EP: 13.Role of Tyrosine Kinase Inhibitors and Gene Therapy in Retinal Diseases

EP: 14.Perspectives on the Future of Retinal Disease Management

Summary

Experts discuss the challenges and considerations associated with incorporating novel therapies like gene therapy or port delivery systems into the early treatment regimens for common retinal diseases. Seenu Hariprasad acknowledges the high bar set for future therapies due to the safety and effectiveness of currently available treatments like aflibercept 8 mg and faricimab. He suggests that a combination of tyrosine kinase inhibitors (TKIs) and gene therapy could be a powerful approach, providing a baseline therapy that can be titrated with anti-VEGF agents. David Brown, MD emphasizes the historical challenges faced with TKIs, particularly issues related to pharmacology. He raises concerns about the potential for gene therapy to cause inflammation and highlights the safety of current treatments. Diana Do, MD expresses the challenge of incorporating gene therapy or other novel therapies early when effective and safe clinic-based options are available. She suggests that these novel therapies may be more suitable for patients with high-frequency treatment needs and without additional risk factors.

This summary was AI-generated and edited for clarity.